Table 2.
Cox proportional‐hazard models for each ventricular arrhythmia outcome according to randomized treatment assignment
| Outcome | Sacubitril/valsartan | Enalapril | Hazard ratio (95% CI) | |||
|---|---|---|---|---|---|---|
| n/N (%) | Event rate per 100 patient years (95% CI) | n/N (%) | Event rate per 100 patient years (95% CI) | Primary analysis a | Adjusted analysis b | |
| Ventricular arrhythmia | 145/4187 (3.5) | 1.6 (1.4–1.9) | 188/4212 (4.5) | 2.1 (1.8–2.4) | 0.76 (0.62–0.95); p = 0.015 | 0.78 (0.62–0.96); p = 0.021 |
| Ventricular arrhythmia/ICD shock/resuscitated cardiac arrest | 165/4187 (3.9) | 1.8 (1.6–2.1) | 207/4212 (4.9) | 2.3 (2.0–2.6) | 0.79 (0.65–0.97); p = 0.025 | 0.81 (0.66–0.99); p = 0.039 |
| VT/VF/ventricular flutter/torsades de pointes | 133/4175 (3.2) | 1.5 (1.2–1.7) | 171/4195 (4.1) | 1.9 (1.6–2.2) | 0.77 (0.62–0.97); p = 0.027 | 0.79 (0.63–0.99); p = 0.043 |
CI, confidence interval; ICD, implantable cardioverter defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia.
Primary analysis included randomized treatment and region.
Adjusted analysis included randomized treatment, region, beta‐blocker use, angiotensin‐converting enzyme inhibitor use, angiotensin receptor blocker use, mineralocorticoid receptor antagonist use, ischaemic aetiology, ejection fraction, presence of ICD or cardiac resynchronization therapy, New York Heart Association class, hypertension, diabetes, past hospitalization for heart failure, estimated glomerular filtration rate, log‐transformed N‐terminal pro B‐type natriuretic peptide.